Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuelle Pourcher

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|September 7, 2007
LRRK2 is not a significant cause of Parkinson's disease in French-CanadiansNicolas Dupré, Jean-Baptiste Rivière, Richard H Myers, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 17, 2013
Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's diseaseStewart A Factor, Kenneth Wolski, Daniel M Togasaki, et al.
Parkinsonism & Related Disorders|September 24, 2013
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's diseaseRajesh Pahwa, Kelly E Lyons, Robert A Hauser, et al.
Archives of Neurology|February 11, 2009
No TARDBP mutations in a French Canadian population of patients with Parkinson diseaseEdor Kabashi, Hussein Daoud, Jean-Baptiste Rivière, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 24, 2012
Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety studyBruno Dubois, Eduardo Tolosa, Regina Katzenschlager, et al.
The Lancet. Neurology|July 11, 2014
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trialRobert A Hauser, C Warren Olanow, Karl D Kieburtz, et al.
Annals of Neurology|January 20, 2025
Adult Neurogenesis in the Subventricular Zone of Patients with Huntington's and Parkinson's Diseases and following Long-Term Treatment with Deep Brain StimulationMarta Snapyan, Francis Desmeules, Jonathan Munro, et al.
Neurobiology of Aging|January 1, 2013
Investigation of C9orf72 repeat expansions in Parkinson's diseaseHussein Daoud, Anne Noreau, Daniel Rochefort, et al.
Clinical Neuropharmacology|January 18, 2014
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized studyMurat Emre, Werner Poewe, Peter Paul De Deyn, et al.
The Lancet. Neurology|January 22, 2019
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trialPeter A LeWitt, Robert A Hauser, Rajesh Pahwa, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|September 7, 2007
LRRK2 is not a significant cause of Parkinson's disease in French-CanadiansNicolas Dupré, Jean-Baptiste Rivière, Richard H Myers, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 17, 2013
Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's diseaseStewart A Factor, Kenneth Wolski, Daniel M Togasaki, et al.
Parkinsonism & Related Disorders|September 24, 2013
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's diseaseRajesh Pahwa, Kelly E Lyons, Robert A Hauser, et al.
Archives of Neurology|February 11, 2009
No TARDBP mutations in a French Canadian population of patients with Parkinson diseaseEdor Kabashi, Hussein Daoud, Jean-Baptiste Rivière, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 24, 2012
Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety studyBruno Dubois, Eduardo Tolosa, Regina Katzenschlager, et al.
The Lancet. Neurology|July 11, 2014
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trialRobert A Hauser, C Warren Olanow, Karl D Kieburtz, et al.
Annals of Neurology|January 20, 2025
Adult Neurogenesis in the Subventricular Zone of Patients with Huntington's and Parkinson's Diseases and following Long-Term Treatment with Deep Brain StimulationMarta Snapyan, Francis Desmeules, Jonathan Munro, et al.
Neurobiology of Aging|January 1, 2013
Investigation of C9orf72 repeat expansions in Parkinson's diseaseHussein Daoud, Anne Noreau, Daniel Rochefort, et al.
Clinical Neuropharmacology|January 18, 2014
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized studyMurat Emre, Werner Poewe, Peter Paul De Deyn, et al.
The Lancet. Neurology|January 22, 2019
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trialPeter A LeWitt, Robert A Hauser, Rajesh Pahwa, et al.
Pageof 4